RenovoRx (RNXT) EBITDA (2020 - 2026)

RenovoRx has disclosed EBITDA across 7 years of filings, most recently posting -$3.3 million for Q2 2026.

• In Q2 2026, EBITDA fell 25.06% year-over-year to -$3.3 million; the TTM figure through Jun 2026 stood at -$13.5 million (down 20.38% YoY), while the FY2025 annual figure was -$12.5 million, down 14.04% from the prior year.
• EBITDA came in at -$3.3 million for Q2 2026 at RenovoRx, up from -$3.5 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$1.8 million in Q4 2023 to a low of -$3.5 million in Q4 2025.
• Average EBITDA over 5 years is -$2.9 million, with a median of -$3.0 million recorded in 2022.
• Year-over-year, EBITDA sank 201.85% in 2022 and rose 24.07% in 2024.
• Over 5 years, EBITDA stood at -$2.2 million in 2022, then grew by 18.11% to -$1.8 million in 2023, then slumped by 48.11% to -$2.6 million in 2024, then sank by 33.81% to -$3.5 million in 2025, then grew by 4.91% to -$3.3 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$3.3 million in Q2 2026, -$3.5 million in Q1 2026, and -$3.5 million in Q4 2025.